Akut mieloid leukémia (AML): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• FLT3 36
• TP53 9
• NPM1 27
• IDH 29
• KMT2A 20
• RUNX1 2
• CD123 19
• BCL-2 10
• ABL1 2
• CD33 17
• PI3K 3
• mTOR 0
• KIT 3
• JAK 1
• CD19 8
• MAPK 0
• STAT3 0
• ERK 0
• AKT 0
• CD38 6
• HDAC 2
• MYC 1
• NRF2 0
• PD-1 4
• PPAR 0
• CXCR4 0
• BRD4 0
• PD-L1 0
• RAS 0
• STING 1
• HIF-1 0
• TIM-3 0
• METTL3 0
• CD47 1
• CTNNB1 0
• JNK 0
• KRAS 0
• MEK 0
• PARP 3
• EZH2 0
• IL-6 2
• BRAF 0
• EGFR 0
• FTO 0
• HSP90 0
• PDGFR 0
• PTEN 0
• CDK4/6 0
• FGFR 2
• GPX4 0
• HMGB1 0
• NLRP3 0
• NRAS 0
• SHP2 0
• AMPK 0
• CD20 1
• IL-15 1
• MDM2 0
• PINK1 0
• PKM2 0

69+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Therapeutic restoration of CUX1 in -7/del(7q) acute myeloid leukemia

  University of Chicago· Chicago, Egyesült Államok· 50 114 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, Egyesült Államok· 390 447 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NINDS · R03

  Uncovering glycoRNA landscape in glioblastoma as a novel layer of immune evasion

  University of Texas Hlth Sci Ctr Houston· Houston, Egyesült Államok· 78 000 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R56

  Cooperation partners of SETBP1 in AML development

  Henry M. Jackson Fdn for the Adv Mil/Med· Bethesda, Egyesült Államok· 149 152 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · R21

  Loss of TET2 Promotes Leukemogenesis by Enhancing NPY-Mediated PRC2 Disruption and CTCFL Chromatin Remodeling

  Indiana University Indianapolis· Indianapolis, Egyesült Államok· 407 543 USD awarded in fiscal year 2026· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)

  Universita Degli Studi di Parma· Parma, Olaszország· EU contribution 193 643 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the immuno-regulatory functions of the human bone marrow niche upon cancer cellular therapy (ImmunhOss)

  Lunds Universitet· Lund, Svédország· EU contribution 2 000 000 EUR· until 2032. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Targeting bioactive lipids to overcome leukemia immune evasion and improve allogeneic hematopoietic stem cell transplantation outcomes (LIFE)

  Universitat Basel· Basel, Svájc· EU contribution 1 499 511 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-ERC

  Integrating DNA Methylation and Drug Abundance at Single-Cell Resolution to Predict Cancer Drug Sensitivity (EPI-SENSOR)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 1 499 423 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-ERC

  Perturbation-based Phosphoproteomics to Study Drug Response Heterogeneity (PerturbPhos)

  Universitatsklinikum Jena· Jena, Németország· EU contribution 1 491 735 EUR· until 2031. szept.

  The disease is named only in the funder's project summary, not in the title.

10 of 499 running projects, newest first. Listed amounts together: 329,0 M USD + 53,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

  NCT05521087· Janssen Research & Development, LLC· Frissítve: 2025. jún. 22.

  “Business Decision”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás

• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Janssen Research & Development, LLC· Forrás

• A Study of Revumenib and Mezigdomide in People With Leukemia

  NCT07356154· Memorial Sloan Kettering Cancer Center· Forrás

• Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

  NCT07355335· Massachusetts General Hospital· Forrás

• Ziftomenib Maintenance Post Allo-HCT

  NCT06440135· Massachusetts General Hospital· Forrás

• A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

  NCT05453903· Janssen Research & Development, LLC· Forrás

• S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation

  NCT07722312· Servier· Forrás

• Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás

• A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

  NCT05886049· National Cancer Institute (NCI)· Forrás

• A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

  NCT05521087· Janssen Research & Development, LLC· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 39
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 17
• Gene Expression Profiling 85
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 7
• Exome Sequencing 1
• Proteomics 28
• Metabolomics 10
• Mass Spectrometry 3
• Flow Cytometry 88
• Immunohistochemistry 14
• Liquid Biopsy 1
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 160
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 11
• Machine Learning 33
• Deep Learning 12
• Cohort Studies 30
• Genome-Wide Association Study 3

• Bidirectional Mendelian Randomization and Multi-Omics Uncover Causal Serum Metabolites and Neuro-Related Mechanistic Pathways in Acute Myeloid Leukemia.

  Int J Mol Sci, 2025. nov.

• Identification and validation of plasma protein biomarkers as therapeutic targets in acute myeloid leukemia: an integrative multi-omics study.

  Front Immunol, 2025. okt.

• Causal effects of vitamin D on leukemia risk: insights from two-sample Mendelian randomization analysis.

  Nutr Hosp, 2025. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.